The study of feasibility and usefulness of olanzapine for the patients who received oxaliplatin chemotherapy.
Phase 2
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000032591
- Lead Sponsor
- Osaka International Cancer Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who has severe dysfunction of liver or kidney 2. Patients who suffered nausea or vomiting before 24 h of the enrollment 3. Patients who used antiemetics before 24 h of the enrollment 4. Patients with symptomatic brain metastasis/carcinomatosis. 5. Patients who had diabetes. 6. Pregnant, breastfeeding or expecting woman. 7. Patient is receiving pimozide 8. Patient is judged inappropriate by the investigator as subject for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of adverse events
- Secondary Outcome Measures
Name Time Method